FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 816 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in... August 12, 2024 Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily... September 16, 2021 For Kids with Medulloblastoma, Trial Suggests Radiation Can Be Tailored July 16, 2021 Woman Helps Students With Special Needs Achieve Success After Graduation December 23, 2021 Load more HOT NEWS How NatWest Group are making a difference this Giving Tuesday Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... Virtual Reality Found to Benefit Cancer Patients’ Mental Health Hormone Replacement Therapy Not Linked with Increased Dementia Risk, Study Finds
